Department of Ophthalmology, University of Lausanne, Lausanne, Switzerland.
The Save Sight and Eye Health Institute, Sydney Medical School, The University of Sydney, Sydney, New South Wales, Australia.
Surv Ophthalmol. 2018 Sep-Oct;63(5):638-645. doi: 10.1016/j.survophthal.2018.02.004. Epub 2018 Feb 22.
The introduction of antivascular endothelial growth factor agents such as ranibizumab and aflibercept has revolutionized the management of neovascular age-related macular degeneration. A number of randomized clinical trials have shown that ranibizumab and aflibercept produce similar efficacy and safety outcomes. Most of the switching studies published to date show that efficacy benefits are uncontrolled, retrospective trials with limitations in terms of their selection, monitoring, numbers, and assessment criteria. Based on the published literature to date, we propose arguments for and against switching antivascular endothelial growth factor agents, provide our own perspective on this topic, and suggest a focus for future research.
抗血管内皮生长因子药物（如雷珠单抗和阿柏西普）的引入彻底改变了新生血管性年龄相关性黄斑变性的治疗方式。多项随机临床试验表明，雷珠单抗和阿柏西普具有相似的疗效和安全性。迄今为止发表的大多数转换研究表明，疗效获益是不可控的，回顾性试验在选择、监测、数量和评估标准方面存在局限性。基于迄今为止发表的文献，我们提出了赞成和反对转换抗血管内皮生长因子药物的理由，提供了我们对这一主题的看法，并提出了未来研究的重点。
